ABSTRACT
UNLABELLED: All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant and 87 nonresponder patients with chronic HCV genotype 1b infection were enrolled at 24 centers in Japan. Patients received daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks. The primary endpoint was sustained virologic response 24 weeks after treatment (SVR24 ). This study is registered with ClinicalTrials.gov (NCT01497834). SVR24 was achieved by 87.4% of interferon-ineligible/intolerant patients and 80.5% of nonresponder (null and partial) patients; rates were similar in cirrhosis (90.9%) and noncirrhosis (84.0%) patients, and in patients with IL28B CC (84.5%) or non-CC (84.8%) genotypes. Fourteen patients in each group (12.6%) discontinued dual therapy, mainly due to adverse events or lack of efficacy. Nine nonresponder patients received additional treatment with peginterferon/ribavirin per protocol-defined criteria. The rate of serious adverse events was low (5.9%) and varied among patients. The most common adverse events were nasopharyngitis, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), headache, diarrhea, and pyrexia. CONCLUSION: Interferon-free, ribavirin-free all-oral therapy with daclatasvir and asunaprevir for 24 weeks is well tolerated and can achieve a high rate of SVR in patients with HCV genotype 1b who were ineligible, intolerant, or had not responded to prior interferon-based therapy. (Hepatology 2014;59:2083-2091).
Subject(s)
Hepatitis C, Chronic/drug therapy , Imidazoles/therapeutic use , Isoquinolines/therapeutic use , Sulfonamides/therapeutic use , Adult , Aged , Carbamates , Drug Therapy, Combination , Female , Hepacivirus/genetics , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/virology , Humans , Imidazoles/adverse effects , Imidazoles/blood , Isoquinolines/adverse effects , Isoquinolines/blood , Male , Middle Aged , Pyrrolidines , RNA, Viral/blood , Sulfonamides/adverse effects , Sulfonamides/blood , Treatment Failure , Valine/analogs & derivatives , Young AdultABSTRACT
BACKGROUND: Limited data are available regarding therapies for hypertrophic cardiomyopathy (HCM). This study assessed the prevalence, clinical characteristics, and treatment patterns of HCM in Japan. METHODS: This retrospective database study analyzed data from 438 hospitals in the Japan Medical Data Vision database from 2016 to 2020. We identified 3913 patients (15â¯%) with obstructive HCM (oHCM) and 21,714 patients (85â¯%) with nonobstructive HCM (nHCM). RESULTS: The estimated total number of patients with oHCM and nHCM in 2020 among Japanese hospitals was 8500 and 43,500, respectively. The prevalence of oHCM and nHCM steadily increased by 27â¯% and 12â¯%, respectively, from 2016 to 2020, with a 1:5.2 ratio of oHCM to nHCM in 2020. The mean age of the oHCM and nHCM populations was 72 and 70â¯years, respectively, and comorbidities included atrial fibrillation (AF) (oHCM, 33.8â¯%; nHCM, 32.2â¯%), other arrythmia (30.1â¯%; 27.6â¯%), and stroke (16.6â¯%; 16.4â¯%). Furthermore, 45.0â¯% of oHCM and 37.7â¯% of nHCM patients had undergone at least one hospitalization. A substantial number of HCM patients aged between 20 and 59â¯years reported AF (oHCM, 17-37â¯%; nHCM, 4-24â¯%) and stroke (oHCM, 0-12â¯%; nHCM, 3-10â¯%). ß-blockers (oHCM, 64.0â¯%; nHCM, 42.1â¯%) were the most frequently prescribed treatment, followed by Na channel blockers (29.5â¯%; 5.7â¯%), calcium channel blockers (18.1â¯%; 8.8â¯%), direct oral anticoagulants (14.5â¯%; 15.2â¯%), and warfarin (11.0â¯%; 11.4â¯%). CONCLUSIONS: This study provides important information on the current epidemiological and clinical characteristics of HCM in Japan.
Subject(s)
Atrial Fibrillation , Cardiomyopathy, Hypertrophic , Stroke , Humans , Young Adult , Adult , Middle Aged , Retrospective Studies , Prevalence , Japan/epidemiology , Cardiomyopathy, Hypertrophic/epidemiology , Cardiomyopathy, Hypertrophic/therapy , Stroke/epidemiology , Atrial Fibrillation/epidemiology , Atrial Fibrillation/therapyABSTRACT
BACKGROUND: Daclatasvir-containing regimens have the potential to address limitations of current regimens combining peginterferon alfa and ribavirin with first-generation protease inhibitors for treatment of chronic HCV genotype 1 infection. METHODS: In this randomized, double-blind study, 27 Japanese treatment-naive patients received once-daily daclatasvir 10 mg or 60 mg or placebo, each combined with peginterferon alfa-2b/ribavirin; 18 prior null (n=9) or partial (n=9) responders received the same daclatasvir-containing regimens without a placebo arm. Daclatasvir recipients with protocol-defined response (HCV RNA<15 IU/ml at week 4, undetectable at week 12) were treated for 24 weeks; those without protocol-defined response and placebo recipients continued treatment to week 48. RESULTS: Sustained virological response 24 weeks post-treatment (SVR24) was achieved by 66.7%, 90.0% and 62.5% of treatment-naive patients in the daclatasvir 10 mg, 60 mg and placebo groups, respectively. Prior non-responders had more frequent virological failure; 22.2% and 33.3% of daclatasvir 10 mg and 60 mg recipients, respectively, achieved SVR24. Adverse events were similar across groups and were typical of peginterferon alfa-2b/ribavirin. Pyrexia, headache, alopecia, decreased appetite and malaise were the most common adverse events; two daclatasvir recipients discontinued due to adverse events. CONCLUSIONS: Daclatasvir 60 mg combined with peginterferon alfa-2b and ribavirin achieved a high rate of SVR24 in treatment-naive patients with HCV genotype 1 infection, with tolerability similar to that of peginterferon alfa-2b/ribavirin alone. However, regimens with greater antiviral potency are needed for prior non-responders.
Subject(s)
Antiviral Agents/therapeutic use , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Imidazoles/therapeutic use , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Adult , Aged , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Carbamates , Drug Therapy, Combination , Female , Hepatitis C, Chronic/virology , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Male , Middle Aged , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Pyrrolidines , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Ribavirin/administration & dosage , Ribavirin/adverse effects , Treatment Failure , Treatment Outcome , Valine/analogs & derivatives , Viral Load , Young AdultABSTRACT
We have synthesized l-type enantiomers (cU and cA) of nucleoside analogues, whose glycosyl bonds are fixed in a low anti conformation (ap glycosyl conformation, [small chi][approximate] 180[degree]), and incorporated them into oligonucleotides to evaluate the hybridization ability with natural DNA and RNA sequences. Although the incorporation of the modified nucleosides into oligonucleotides decreased the hybridization ability with unmodified complementary DNA sequences, the fully-substituted 12mers (cU(12) and cA(12)) still retained the hybridization ability with the complementary unmodified DNA 12mers, regardless of their unnatural l-chirality. In contrast, cU(12) and cA(12) showed different hybridization behavior with complementary unmodified RNA 12mers. cU(12) forms a more stable duplex with rA(12) than the corresponding natural 12mer (dT(12)), whereas cA(12) cannot hybridize with rU(12). Based on the model structure of cU(12)-rA(12), we discuss these experimental results.